Whitney & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Whitney & Co’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13	Closed	-$1K	–	290
2018 Q3	$1K	Buy	+13	New	+$1.96K	﹤0.01%	508

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Whitney & Co's LGND Position: Q4 2018 in Review

Whitney & Co sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 13 shares — an estimated $1K sold.

Whitney & Co first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Whitney & Co reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 13 Ligand Pharmaceuticals shares in Q4 2018, an estimated $1K.
Whitney & Co first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Whitney & Co's Ligand Pharmaceuticals position peaked at $1K in Q3 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.